Pacific Biosciences of California, Inc. May Have Violated Securities Laws And Stockholders Can Help The Schall Law Firm Investigate

LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. PacBio preannounced poor top-line results for the first quarter of 2024 on April 16, 2024. The Company also announced a reduction in its full-year guidance for 2024 and revised its long-term guidance for fiscal year 2026. The Company blamed its shortfalls on "an increasing number of customers delay instrument purchases and we experienced some unexpected softness in consumable shipments." Analysts were alarmed by the Company’s performance, indicating it was "far worse than we expected."

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View the original press release on accesswire.com

COMTEX_457922542/2457/2024-09-19T11:03:57